234 related articles for article (PubMed ID: 7482824)
1. Review and preview of anti-T-cell antibodies.
Helderman JH
Transplant Proc; 1995 Oct; 27(5 Suppl 1):8-9. PubMed ID: 7482824
[No Abstract] [Full Text] [Related]
2. Selective immunosuppression with anti-T cell monoclonal antibodies.
Chatenoud L; Bach JF
Clin Nephrol; 1992; 38 Suppl 1():S53-60. PubMed ID: 1295709
[TBL] [Abstract][Full Text] [Related]
3. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation.
Goldstein G
Transplant Proc; 1987 Apr; 19(2 Suppl 1):1-6. PubMed ID: 3105134
[No Abstract] [Full Text] [Related]
4. Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival.
Shield CF
Transplant Proc; 1993 Apr; 25(2 Suppl 1):81-2. PubMed ID: 8465434
[No Abstract] [Full Text] [Related]
5. Influence of pretransplant antibodies on early renal allograft rejection.
Alarif L; Rodriguez R; Blackburn S; Light JA
Transplant Proc; 1987 Feb; 19(1 Pt 1):771-2. PubMed ID: 3274869
[No Abstract] [Full Text] [Related]
6. New insights into therapy with monoclonal antibodies in allograft transplantation.
Schena FP
Nephrol Dial Transplant; 1997; 12 Suppl 1():55-8. PubMed ID: 9075230
[No Abstract] [Full Text] [Related]
7. Biological immunosuppressants: the way to clinical transplantation tolerance.
Chatenoud L
Transplant Proc; 1997; 29(1-2):51-5. PubMed ID: 9123108
[No Abstract] [Full Text] [Related]
8. The clinical application of monoclonal antibody therapies in renal transplantation.
Dhanireddy KK; Xu H; Mannon RB; Hale DA; Kirk AD
Expert Opin Emerg Drugs; 2004 May; 9(1):23-37. PubMed ID: 15155134
[TBL] [Abstract][Full Text] [Related]
9. First and second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection followed by testing for anti-OKT3 IgM and/or IgG immunization.
Birkeland SA; Bach JF; Chatenoud L; Jørgensen KA; Strate M; Elbirk A; Rohr N; Svendsen V
Transplant Proc; 1990 Feb; 22(1):221-2. PubMed ID: 2106740
[No Abstract] [Full Text] [Related]
10. Effect of HLA matching and T- and B-cell crossmatch on acute rejection and graft survival following liver transplantation.
Chen M; Wade J; Levy GA; Greig PD
Transplant Proc; 1994 Oct; 26(5):2695-6. PubMed ID: 7940844
[No Abstract] [Full Text] [Related]
11. OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses.
Norman DJ; Barry JM; Bennett WM; Munson JL; Meyer M; Henell K; Kimball J; Hubert B
Transplant Proc; 1991 Feb; 23(1 Pt 2):1052-4. PubMed ID: 1846453
[No Abstract] [Full Text] [Related]
12. Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection.
Lazarovits AI; Rochon J; Banks L; Hollomby DJ; Muirhead N; Jevnikar AM; White MJ; Amlot PL; Beauregard-Zollinger L; Stiller CR
Transplant Proc; 1993 Feb; 25(1 Pt 1):820-2. PubMed ID: 7679844
[No Abstract] [Full Text] [Related]
13. Comparison of T10Bg.1A-31 and OKT3 in treating acute renal allograft rejection.
Lucas BA; Waid TH; Thompson JS; Brown SA; Munch LC; McKeown JW; Kryscio RJ; Prebeck RJ
Transplant Proc; 1993 Feb; 25(1 Pt 1):543-5. PubMed ID: 8438406
[No Abstract] [Full Text] [Related]
14. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab.
Alausa M; Almagro U; Siddiqi N; Zuiderweg R; Medipalli R; Hariharan S
Clin Transplant; 2005 Feb; 19(1):137-40. PubMed ID: 15659147
[TBL] [Abstract][Full Text] [Related]
15. Treatment of acute rejection with anti-T-cell antigen receptor complex alpha beta (T10B9.1A-31) or anti-CD3 (OKT3) monoclonal antibody: results of a prospective randomized double-blind trial.
Waid TH; Lucas BA; Thompson JS; Munch LC; Brown S; Kryscio R; Prebeck R; VanHoy MA; Jezek D
Transplant Proc; 1991 Feb; 23(1 Pt 2):1062-5. PubMed ID: 1899152
[No Abstract] [Full Text] [Related]
16. Immunologic monitoring in OKT3-treated kidney graft recipients.
Zlabinger GJ; Maurer D; Ulrich W; Meron G; Pohanka E; Kovarik J
Transplant Proc; 1990 Aug; 22(4):1777-8. PubMed ID: 2117807
[No Abstract] [Full Text] [Related]
17. Antimurine antibody to OKT3 in cardiac transplantation: implications for prophylaxis and retreatment of rejection.
O'Connell JB; Bristow MR; Hammond EH; Menlove RL; Ensley RD; Ratkovec RM; Renlund DG
Transplant Proc; 1991 Feb; 23(1 Pt 2):1157-9. PubMed ID: 1899154
[No Abstract] [Full Text] [Related]
18. OKT3 prophylaxis in kidney transplant recipients: drug monitoring by flow cytometry.
Cinti P; Cocciolo P; Evangelista B; Orlandini AM; Bruzzone P; Renna Molajoni E; Cortesini R
Transplant Proc; 1996 Dec; 28(6):3214-6. PubMed ID: 8962245
[No Abstract] [Full Text] [Related]
19. Immunological follow-up of renal allograft recipients treated with the BMA 031 (anti-TCR) monoclonal antibody.
Chatenoud L; Ferran C; Legendre C; Kurrle R; Kreis H; Bach JF
Transplant Proc; 1990 Aug; 22(4):1787-8. PubMed ID: 2117809
[No Abstract] [Full Text] [Related]
20. Use of antilymphocyte induction therapy in liver transplantation: A European perspective.
Langrehr JM; Neuhaus PJ
Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S71-84. PubMed ID: 10431020
[No Abstract] [Full Text] [Related]
[Next] [New Search]